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Background: The purpose of this study was to investigate plasma levels of thrombin activatable fibrinolysis
inhibitor (TAFI) and TAFI’s relationship with coagulation markers (prothrombin fragment 1 + 2) in gastric cancer
patients.
Methods: Thirty-three patients with gastric adenocarcinoma and 29 healthy control subjects were prospectively
enrolled in the study. Patients who had a history of secondary malignancy, thrombosis related disease, oral
contraceptive use, diabetes mellitus, chronic renal failure or similar chronic metabolic disease were excluded from
the study. A fasting blood sample was drawn from patients to determine the plasma levels of TAFI and
Prothrombin Fragment 1 + 2 (F 1 + 2). In addition, data on patient age, sex, body mass index (BMI) and stage of
disease were recorded. The same parameters, except stage of disease, were also recorded for the control group.
Subsequently, we assessed the difference in the levels of TAFI and F 1 + 2 between the patient and control groups.
Moreover, we investigated the relation of TAFI and F 1 + 2 levels with age, sex, BMI and stage of disease in the
gastric cancer group.
Results: There were no statistical differences in any demographic variables (age, gender and BMI) between the
groups (Table 1). The mean plasma TAFI levels of the gastric cancer group (69.4 ± 33.1) and control group
(73.3 ± 27.5) were statistically similar (P= 0.62). The mean plasma F 1 + 2 level in the gastric cancer group was
significantly higher than for those in the control group (549.7 ± 325.3 vs 151.9 ± 67.1, respectively; P< 0.001). In the
gastric cancer group, none of the demographic variables (age, gender and BMI) were correlated with either TAFI or
F 1 + 2 levels. Also, no significant associations were found between the stage of the cancer and either TAFI or F
1 + 2 levels.
Conclusion: In our study, TAFI levels of gastric cancer patients were similar to healthy subjects. The results of our
study suggest that TAFI does not play a role in pathogenesis of the hypercoagulable state in gastric cancer
patients.
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The association between cancer and venous thrombo-
embolism (VTE) is well-established. The overall risk of
thrombosis in cancer patients is seven-fold that of non-
cancer patients and up to 20% of cancer patients develop
VTE. Venous thromboembolism (VTE), which includes
both deep vein thrombosis (DVT) and pulmonary em-
bolism (PE), is the second leading cause of death in hos-
pitalized and ambulatory cancer patients [1-4]. The
probability of thrombosis occurring in a cancer patient
is dependent on several factors, including the type of
cancer, the clinical stage, accompanying medical pro-
blems, performance status and the treatment modalities
employed. Tumor cells can stimulate blood coagulation
through various mechanisms, including production of
pro-coagulant, fibrinolytic and pro-aggregating activities;
release of pro-inflammatory and pro-angiogenic cyto-
kines; and direct interaction with blood and host vascu-
lar cells (for example, platelets, leukocytes and
endothelial cells) and through adhesion molecules.
Thrombin Activatable Fibrinolysis Inhibitor (TAFI) is
a single chain glycoprotein zymogen (Mr = 60,000)
synthesized in the liver and circulating at a plasma
concentration of 50 nM. TAFI is proposed to play a
key role in the interactions among procoagulant, anti-
coagulant and fibrinolytic systems [5-9]. Effective fi-
brinolysis results from the formation of a ternary
complex among tPA, plasminogen and C-terminal ly-
sine residues on fibrin. Plasminogen bound to fibrin is
more effectively converted to plasmin, thereby localiz-
ing the lytic activity to the area of the clot. Plasmin
degradation of fibrin generates additional C-terminal ly-
sine residues thereby amplifying the system locally. The
ability of TAFI to bind specifically to plasminogen and
to cleave C-terminal lysines on fibrin (and cell surfaces)
results in down-regulation of fibrinolysis by reducing
the number of plasminogen and tPA binding sites on
fibrin. The activation of TAFI by the thrombin/throm-
bomodulin complex couples both the phenomenon of
coagulation induced inhibition of fibrinolysis and the
profibrinolytic effect of activated protein C. Increased
plasma levels of TAFI were reported to be a contribut-
ing factor of thrombotic disorders in some kinds of
cancers, such as breast and lung cancers.
The aim of the present study was to investigate plasma
levels of TAFI and TAFI’s relationship with coagulation




Thirty-three patients, who presented with the diagnosis of
gastric adenocarcinoma between January and December
2011 in the General Surgery and Medical OncologyClinics of our institution, were prospectively enrolled in
the study. Patients with a history of secondary malig-
nancy, thrombosis related disease, oral contraceptive use,
diabetes mellitus, chronic renal failure or similar chronic
metabolic disease were excluded from the study. The con-
trol group consisted of 29 healthy subjects with similar
demographic characteristics to the gastric cancer group.
All subjects gave informed consent to participate in the
study and the study protocol was approved by the institu-
tional ethical committee.
A fasting blood sample was drawn from patients to de-
termine the plasma levels of TAFI and prothrombin
fragment 1 + 2 (F 1 + 2). In addition, data on patient age,
sex, body mass index (BMI) and stage of disease were
recorded. The same parameters, except stage of disease,
were also recorded for the control group. Subsequently,
we assessed the difference in the levels of TAFI and F
1 + 2 between the patient and control groups. Moreover,
we investigated the relation of TAFI and F 1 + 2 levels
with age, sex, BMI and stage of disease in the patient
groups.
Measurement methods
Blood samples were collected by atraumatic venipuncture
without pressure into plastic tubes containing 0.129 M/
0,109 M trisodium citrate anticoagulant (using a ratio of
9:1 volumes).
Thrombin-activatable fibrinolysis inhibitor functional
activity was assayed using the ActichromeW TAFI Activ-
ity kit (American diagnostica Inc., CT, USA). The TAFI
level is determined by first incubating the plasma with a
TAFI Activation Reagent, a specially formulated throm-
bin/thrombomodulin complex that converts the TAFI to
its activated form, TAFIa. An Activation Stop Reagent is
then added to halt the activation step. Next, the TAFI
Developer containing the substrate is added to the
plasma sample and an enzymatic reaction begins. The
reaction is stopped by the addition of sulfuric acid and
the absorbance of the solution is read in a spectropho-
tometer at 490 nm. Plasma that was not activated (not
incubated with the TAFI Activation Reagent) is assayed
in parallel as a control. The difference in absorbance be-
tween the activated and non-activated plasma, ΔA490, is
calculated and represents the amount of TAFI activity in
the sample. The TAFI concentration is determined by
directly interpolating the ΔA490 with the absorbances
generated by a TAFIa standard curve.
F 1 + 2 was measured with a sandwich enzyme–linked
immunosorbent assay method (Enzygnost F 1 + 2
micro). The sandwich assay makes use of two poly-
clonal antibodies against prothrombin and F 1 + 2. The
catching antibodies, which are immobilized on microti-
ter plates, were raised in rabbits against a 14 amino
acid negatively charged synthetic peptide corresponding
Table 2 Plasma levels of TAFI and F 1+2 in the groups
Variables Groups P-value
Gastric cancer Control
TAFI Level ± SD (ng/ml) 69.4 ± 33.1 73.3 ±27.5 0.41
F 1+ 2 Level (pmol/l) 549.7 ± 325.3 151.9 ± 67.1 <0.001*
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react with intact prothrombin. The other antibody (poly-
clonal, rabbit) reacts with prothrombin and F 1 + 2. It
has been coupled to peroxidase. The enzyme activity is
determined with the substrate o-phenylenediamine in
the presence of hydrogen peroxide. The test kit Enzyg-
nost F 1 + 2 micro (Dade Behring, Marburg, Germany),
contains all the necessary reagents to perform the assay.
The standard curve ranges from 0.04 to 10 nmol/L. The
F 1 + 2 concentration is determined by directly interpol-
ating the ΔA492 (490 to 500 nm) with the absorbances
generated by a F 1 + 2 standard curve.
Statistic analysis
Statistical analysis was performed using SPSS for Win-
dows 17 (SPSS Inc., IL,USA). Data are presented as
mean ± standard deviation and percentage. The groups
were compared using the Chi-square test and the
Mann–Whitney U test for categorical or continuous
variables, respectively. P-values less than 0.05 were con-
sidered statistically significant.
Results
There were no statistical differences in any demographic
variables (age, gender and BMI) between the groups
(Table 1). The mean plasma TAFI levels of the gastric
cancer group (69.4 ± 33.1 ng/ml) and the control group
(73.3 ±27.5 ng/ml) were statistically similar (P= 0.62)
(Table 2). The mean plasma F 1 + 2 level in the gastric
cancer group was significantly higher than those in the
control group (549.7 ± 325.3 pmol/l vs 151.9 ± 67.1
pmol/l, respectively; P < 0.001) (Table 2). In the gastric
cancer group, none of the demographic variables (age,
gender and BMI) were correlated with either TAFI or F
1 + 2 levels (Table 3). Also, no significant associations
were found between the stage of the cancer and either
TAFI or F 1 + 2 levels (Table 3).
Discussion and conclusion
Cancer-related thrombosis was first recognized by Bouil-
lard in 1823 and then described by Trousseau in 1844.
Many studies have since provided significant evidence
for a relationship between thrombosis and cancer. The
relationship between the hemostatic system and cancer
was shown by a study conducted by Miller et al. [10],
which investigated hemostatic status every year for fourTable 1 Demographic characteristics of the groups
Variables Groups P-value
Gastric cancer Control
Gender (F/M) 14/19 14/15 0.644
Age ± SD (Years) 61.1 ± 11.5 64.1 ± 6.8 0.235
BMI ± SD (kg/m2) 25.6 ± 2.8 26.4 ± 2.1 0.239years in a population of about 3,000 middle-aged men
without cancer. Among patients with activation of the
hemostatic system (defined as persistent elevation of F
1 + 2 levels and fibrinopeptide A), total mortality was
considerably higher in participants with constant activa-
tion (17.1/1,000 person-years) than in patients without
activation (9.7/1,000 person-years; P= 0.015). This differ-
ence was attributable to an increased incidence of death
from cancers (11.3/1,000 vs. 5.1/1,000 person-years),
mainly due to a three-fold higher mortality from cancers
of the digestive tract (6.3/1,000 vs. 1.9/1,000 person-
years).
Thrombin activatable fibrinolysis inhibitor (TAFI),
also known as plasma procarboxypeptidase B or U, is a
60 kD glycoprotein [5-9]. The main source of TAFI pro-
duction is liver cells under physiological conditions, and
it may act as an acute phase reactant during inflamma-
tion, as demonstrated in mice [11,12]. In addition to
liver cells, adipocytes, endothelial and epithelial cells
may also produce and secrete TAFI in vitro [13,14].
TAFI returns the active carboxypeptidase B or U form
(TAFIa, 35.8 kDa), and modulates fibrinolysis in vivo by
cleaving the C-terminal lysine residues from partially
degraded fibrin [6,9]. The reduction of the C-terminal
lysine residues could thus inhibit the augmentation of
plasminogen activation by tissue plasminogen activator
(t-PA). Moreover, plasmin could also activate TAFI to
TAFIa and inactivate TAFI to a 44.3-kDa fragment, de-
pending on the cleavage site [10]. Therefore, TAFI can
be influenced by both coagulation and fibrinolysis, espe-
cially when hemostasis is disrupted. Various pathological
conditions, including hemophilia, coronary heart disease
(CHD), disseminated intravascular coagulation (DIC),
deep venous thrombosis (DVT) and malignancies result
in different changes in TAFI levels [15-19]. Elevated
TAFI levels were observed in CHD and DVT, which are
thought to be caused by increased levels of coagulation
factors and consequently increased fibrin clot formation
[19,20]. DIC is also characterized by increased coagula-
tion throughout the body. Reduction of TAFI levels was
reported in DIC as well as in sepsis, in which a signifi-
cant depletion of TAFI was observed in the presence of
pathogens in plasma [16]. These results suggest that the
consumption of TAFI is an important contributing fac-
tor in the pathogenesis of DIC and sepsis.
Hataji et al. reported that the plasma level of TAFI
was significantly increased in lung cancer patients
Table 3 TAFI and F 1+ 2 levels by gender, age, BMI and stage in the gastric cancer group
TAFI Level P-value F 1+ 2 Level P-value
Gender Female 63.6 ± 22.7 0.32 483.7 ± 230.8 0.28
Male 73.6 ± 39.1 598.3 ±379.2
Age >60 (n= 21) 67.7 ± 32.1 0.52 614± 337.8 0.11
≤60 (n = 12) 73.5 ± 37.1 437.2 ± 280.5
BMI >25 (n= 15) 65.7 ± 31.8 0.34 583.7 ± 328.7 0.47
≤25 (n = 18) 74.8 ± 34.8 521.3 ± 329.1
Stages Stage 1a (n= 1) 93.3 0.92 484 0.81
Stage 1b (n= 0) - -
Stage 2 (n= 5) 68.2 ± 21.3 416.8 ± 80.9
Stage 3a (n= 14) 69 ± 23. 609.5 ± 354.7
Stage 3b (n= 4) 71.8 ± 34 575± 498.7
Stage 4 (n= 9) 66.9 ± 51.9 526.6 ± 321
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tration of TAFI was particularly found higher in patients
with small cell carcinoma compared to those with
adenocarcinoma or squamous cell carcinoma, and in
cancer patients that responded to chemotherapy com-
pared to non-responders [21]. Similar to Hataji et al.,
Koldas et al. found increased circulating levels of TAFI
in patients with non-small cell lung cancer. However, in
their study, there were no statistically significant rela-
tionships between TAFI levels and patient age, sex, BMI,
histopathology or stage of disease. Balcik et al. reported
significantly elevated TAFI levels in patients with mul-
tiple myeloma. Futhermore, they demonstrated that
higher TAFI levels were associated with a more
advanced disease stage [22]. Likewise, Kaftan et al.
reported that the plasma level of TAFI was significantly
increased in breast cancer patients compared to healthy
subjects [23].
The mechanism of increased circulating levels of TAFI
in cancer patients is not clear. Inflammatory cytokines
induced by malignant cells may stimulate the production
and secretion of TAFI from liver or vascular endothelial
cells and thus increase its systemic circulation. Besides,
Hataji et al. reported that lung cancer cell lines, particu-
larly small cell lung cancer cell lines, can express the
mRNA and protein of TAFI, suggesting that malignant
cells may also be a direct source of TAFI in cancer
patients [21]. In addition to causing systemic activation
of the blood coagulation system, secretion of TAFI from
cancer cells may increase intra-tumoral fibrin deposition
and thus promote the growth and dissemination of
tumor cells [24].
The prothrombin fragment 1–2 (F 1 + 2) is released
when activated factor X cleaves prothrombin to throm-
bin, and it reflects the in vivo thrombin generation. F
1 + 2 were demonstrated as independent and predictive
of the occurrence of VTE in cancer patients [25].To our knowledge, the present study is one of the first
to investigate the relationship between gastric cancer
and TAFI levels. We found significantly higher F 1 + 2
levels in gastric cancer patients compared to healthy
subjects, suggesting that the risk of thrombosis in gastric
cancer patients was markedly increased. However, in our
study, the TAFI levels of gastric cancer patients were
similar to healthy subjects. The results of our study sug-
gest that TAFI does not play a role in pathogenesis of
the hypercoagulable state in gastric cancer patients.
Contrary to this, in a very recent study by Fidan et al.,
TAFI levels were found to be higher in patients with gas-
tric cancer than in healthy control subjects [26].
As conclusion, the results of our study demonstrated
that the risk of thrombosis was markedly increased in
gastric cancer patients. However, in these patients, any
relationship between increased risk of thrombosis and
TAFI levels could not be found. Even though much has
been elucidated about the pathogenesis of cancer-related
thrombosis, we are indeed beginning to comprehend the
relationship between cancer cells and their related
microenvironment, and in our opinion, such research is
likely to increase our knowledge of cancer-related
thrombosis mechanisms.
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